Silence Therapeutics plc
SLN · XNASCIK 1479615fmd_1PKTVE6JZ7XRMMSJZHF3N9CYV0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 17 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | 22 | 32 | 43 | 1 |
| Cost of revenue | 13 | 13 | 12 | 0 |
| Gross profit | 8 | 19 | 31 | 0 |
| Research and development | 44 | 57 | 68 | 68 |
| Operating income | (61) | (64) | (63) | (91) |
| Income before taxes | (50) | (53) | (44) | (89) |
| Income tax expense | 1 | 1 | 1 | 0 |
| Net income from continuing operations | (50) | (54) | (45) | (89) |
| Net income | (50) | (54) | (45) | (89) |